About Povetacicept
Posted: Sun Feb 16, 2025 5:00 am
"Zai Lab's deep R&D and commercial capabilities, as well as its regional footprint, make it an ideal partner as we work to bring Pove to patients in China and beyond," said Reshma Kewalramani, Ph., CEO and President of Vertex. "We are very pleased to be working with Zai Lab, which will enable us to accelerate the delivery of this potentially best-in-class therapy to the patients who are waiting."
Dr. Ying Du, Founder, Chairman and CEO of Zai Lab, said: "Pove is an important expansion of our existing product portfolio and will continue to strengthen our leading position in immunology in China. We are committed to bringing innovative therapies to patients in need and are pleased to work with Vertex to make Pove available to patients in China and beyond."
Povetacicept is a recombinant fusion protein therapy that is a ivory coast telegram data dual antagonist of BAFF B-cell activating factor and APRIL proliferation-inducing ligand, several cytokines that play key roles in the pathogenesis of multiple autoimmune diseases through their roles in the activation, differentiation andor survival of B cells, T cells and innate immune cells. Based on an engineered TACI transmembrane activator and calmodulin ligand interactor domain, povetacicept has higher binding affinity and greater potency than other BAFF andor APRIL inhibitors in preclinical studies and has demonstrated potential best-in-class efficacy in clinical studies in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also being developed for the treatment of a variety of serious B-cell-mediated diseases, including other autoimmune kidney diseases and autoimmune cytopenias.
Dr. Ying Du, Founder, Chairman and CEO of Zai Lab, said: "Pove is an important expansion of our existing product portfolio and will continue to strengthen our leading position in immunology in China. We are committed to bringing innovative therapies to patients in need and are pleased to work with Vertex to make Pove available to patients in China and beyond."
Povetacicept is a recombinant fusion protein therapy that is a ivory coast telegram data dual antagonist of BAFF B-cell activating factor and APRIL proliferation-inducing ligand, several cytokines that play key roles in the pathogenesis of multiple autoimmune diseases through their roles in the activation, differentiation andor survival of B cells, T cells and innate immune cells. Based on an engineered TACI transmembrane activator and calmodulin ligand interactor domain, povetacicept has higher binding affinity and greater potency than other BAFF andor APRIL inhibitors in preclinical studies and has demonstrated potential best-in-class efficacy in clinical studies in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also being developed for the treatment of a variety of serious B-cell-mediated diseases, including other autoimmune kidney diseases and autoimmune cytopenias.